Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

NSCLC: Amivantamab for Patients With EGFR Exon 20 Insertion Mutations

November 11th 2021

Considerations for the FDA approval and practical use of amivantamab in patients with EGFR exon 20 insertion mutations in non-small cell lung cancer.

Dr. Langer on the Need for Reflex Testing in NSCLC

November 10th 2021

Corey J. Langer, MD, discusses the need for reflex testing in patients with non–small cell lung cancer.

Dr. Lazar on Risk Stratification for Chemotherapy and Adjuvant Therapy in Lung Cancer

November 10th 2021

John F. Lazar, MD, discusses risk stratification for chemotherapy and adjuvant therapy in lung cancer.

Dr. Bordoni on the Utility of Adjuvant Osimertinib in ​EGFR-Mutant Lung Cancer

November 10th 2021

Rodolfo Bordoni, MD, discusses the utility of ​adjuvant osimertinib in lung cancer.

FDA Grants Fast Track Status to Bemcentinib Combo for STK11-Altered Advanced or Metastatic NSCLC

November 9th 2021

The FDA granted a fast track designation to the selective AXL inhibitor bemcentinib in combination with a PD-1/PD-L1 agent in the treatment of patients with STK11-altered advanced or metastatic non–small cell lung cancer without actionable mutations.

Enhanced Grasp of Oncogenic Drivers Leads to Expanded Treatment Options in NSCLC

November 9th 2021

An increased understanding of the biology of non–small cell lung cancer has led to a significant increase in therapeutic options for patients.

Rapid Readouts: 3-Year Overall Survival Update From the Phase 3 CASPIAN Study

November 9th 2021

Afshin Dowlati, MD, discusses data from the following presentation: “Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the Phase 3 CASPIAN study.” (Paz-Ares, ESMO 2021, LBA61)

Dr. Saxena on a Challenging Case of NSCLC

November 8th 2021

Ashish Saxena, MD, PhD, discusses a challenging case of a patient with non–small cell lung cancer.

Dr. Zauderer on the Importance of Optimizing Care in Mesothelioma

November 8th 2021

Marjorie G. Zauderer, MD, discusses the importance of optimizing care for patients with mesothelioma.

Overcoming Mechanisms of Resistance Remains at the Forefront for EGFR-Mutant NSCLC

November 8th 2021

Although next-generation TKIs have helped to overcome resistance in EGFR-mutated non–small cell lung cancer, a more complete understanding of resistance mechanisms may lead to the ability to overcome resistance to the next generation of these drugs.

Future of Lung Cancer Treatment Looks Bright With Emerging Technologies, Novel Discoveries

November 8th 2021

Mark G. Kris, MD, discusses recent progress in non–small cell lung cancer and small cell lung cancer, efforts being made to address unmet needs in these paradigms, and ongoing research that is generating excitement.

Clinical Management of NTRK+ Advanced NSCLC

November 8th 2021

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with NTRK+ NSCLC. They also summarize recent clinical data for agents that target NTRK.

Examining New Approaches to Management of Immune-Related AEs in Lung Cancer

November 6th 2021

With the rise of immunotherapy, patients with lung cancer are experiencing improved outcomes that have allowed for prolonged survival, but it is important to ensure that the adverse effects associated with these novel agents are effectively managed so that their achieved efficacy does not come at the cost of quality of life.

Immunotherapy/Chemo Combos Remain Go-To Option in Growing Small Cell Lung Cancer Paradigm

November 6th 2021

Chemoimmunotherapy is the new frontline standard of care for patients with small cell lung cancer, and other novel agents, such as, bispecific T-cell engagers are in the pipeline and gaining momentum for those who experience disease progression.

Timing of Immunotherapy Stoppage in Lung Cancer Varies Depending on Progression, AEs, and Cure

November 6th 2021

Each situation for stopping immunotherapy in lung cancer has its own complex nuances to consider before the decision is made to cease treatment.

Dr. Brahmer on the Utility of Consolidative Immunotherapy Vs Targeted Therapy in NSCLC

November 6th 2021

Julie Renee Brahmer, MD, MSc, discusses questions regarding the role of consolidative immunotherapy vs targeted therapy in locally advanced non–small cell lung cancer.

Dr. Kris on Next Steps to Improve Outcomes in Lung Cancer

November 6th 2021

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the next steps to improve outcomes for patients with lung cancer.

Dr. Ivanick on Advances in Interventional Pulmonology

November 5th 2021

Nathaniel Ivanick, MD, FCCP, discusses advancements in interventional pulmonology.

Dr. Seetharamu on Utilizing a Patient-Centered Treatment Approach in Lung Cancer

November 5th 2021

Nagashree Seetharamu, MD, MBBS, discusses the importance of utilizing a patient-centered treatment approach in lung cancer.

Dr. Zauderer on Emerging Treatment Strategies in Mesothelioma

November 5th 2021

Marjorie G. Zauderer, MD, discusses emerging treatment strategies in mesothelioma.

NEXT PAGE
PREVIOUS PAGE